Celldex Therapeutics (NASDAQ:CLDX) Releases Earnings Results, Beats Estimates By $0.05 EPS

Celldex Therapeutics (NASDAQ:CLDX) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.05, Zacks reports. Celldex Therapeutics had a negative net margin of 2,385.57% and a negative return on equity of 29.55%. The business had revenue of $2.50 million for the quarter, compared to analysts’ expectations of $1.13 million.

Celldex Therapeutics Stock Up 0.6 %

Shares of NASDAQ:CLDX traded up $0.21 during midday trading on Friday, reaching $32.92. The company had a trading volume of 341,074 shares, compared to its average volume of 788,859. Celldex Therapeutics has a 1-year low of $22.11 and a 1-year high of $53.18. The stock has a market cap of $2.17 billion, a PE ratio of -11.55 and a beta of 1.58. The business’s 50 day moving average price is $36.55 and its 200 day moving average price is $38.84.

Insider Activity at Celldex Therapeutics

In other Celldex Therapeutics news, CFO Samuel Bates Martin sold 35,000 shares of the business’s stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $34.05, for a total transaction of $1,191,750.00. Following the transaction, the chief financial officer now owns 25,128 shares of the company’s stock, valued at approximately $855,608.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, VP Elizabeth Crowley sold 38,597 shares of the firm’s stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $33.64, for a total value of $1,298,403.08. Following the completion of the sale, the vice president now directly owns 9,074 shares in the company, valued at approximately $305,249.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Samuel Bates Martin sold 35,000 shares of the business’s stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $34.05, for a total value of $1,191,750.00. Following the transaction, the chief financial officer now directly owns 25,128 shares in the company, valued at approximately $855,608.40. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 266,332 shares of company stock valued at $9,155,821. Insiders own 3.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on CLDX. Wolfe Research started coverage on Celldex Therapeutics in a report on Tuesday, June 11th. They set an “outperform” rating and a $51.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research report on Tuesday, July 30th. HC Wainwright restated a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a research report on Tuesday, July 30th. Finally, Stifel Nicolaus assumed coverage on shares of Celldex Therapeutics in a research note on Tuesday, June 18th. They issued a “buy” rating and a $58.00 target price on the stock. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, Celldex Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $62.17.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.